

CLAIMS

What is claimed is:

1. A solid biomaterial, characterized in that it essentially comprises:
 - (1) at least one solid support material consisting of at least one insolubilized dextran derivative of general formula $DMC_aB_bSu_cS_d$ in which:

D represents a polysaccharide chain, preferably consisting of successions of glucoside units,

MC represents methyl carboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups (sulfation of the free hydroxyl functional groups carried by the glucoside units),

S represents sulfonate groups (sulfation of the aromatic rings of the B groups),

a, b, c and d represent the degree of substitution (ds), expressed relative to the number of free hydroxyl functional groups in a glucoside unit of the dextran, respectively in MC, B, Su and S groups; a being ≥ 0.3 , b being equal to 0 or ≥ 0.2 , c being equal to 0 or ≥ 0.1 and d being equal to 0 or ≤ 0.15 , provided that when b is equal to 0, c is not equal to 0, and
 - (2) at least one growth factor exhibiting activity on the osteoarticular, dental and/or maxillofacial tissues.

A biomaterial, characterized in that it essentially comprises:

2. The biomaterial as claimed in claim 1, characterized in that said insolubilized dextran derivative is such that d is equal to 0.

- Sub A1*
3. The biomaterial as claimed in claim 1 or claim 2, characterized in that said growth factor is selected from the group consisting of EGFs, IGFs, FGFs, TGF- β s, PDGFs and BMPs.

- Sub A2*
4. The biomaterial as claimed in any one of the preceding claims, characterized in that said growth factor has an osteoinductive activity and is a BMP.

Sub A3

5. The biomaterial as claimed in any one of the preceding claims, characterized in that it comprises several insolubilized dextran derivatives and/or several growth factors involved in the bone reconstruction process.

Sub A4

6. The biomaterial as claimed in any one of the preceding claims, characterized in that it is insolubilized by crosslinking with the aid of a crosslinking agent.

7. The biomaterial as claimed in claim 6, characterized in that said crosslinking agent is selected from the group consisting of sodium trimetaphosphate, epichlorohydrin, divinyl sulfone, gluteraldehyde and bisepoxiranes.

Sub A5

8. The biomaterial as claimed in any one of the preceding claims, characterized in that it exists in the form of a hydrogel.

Sub A6

9. The biomaterial as claimed in any one of claims 1 to 7, characterized in that it exists in the form of a freeze-dried powder.

Sub A7

10. The biomaterial as claimed in claim 9, characterized in that said freeze-dried powder is obtained from the hydrogel defined in claim 8.

Sub A8

11. The biomaterial as claimed in any one of the preceding claims, characterized in that it comprises, in addition, a tissue filling material.

12. The biomaterial as claimed in claim 11, characterized in that it coats particles of an inorganic or polymeric insoluble support, said particles having a diameter greater than 100 µm.

Sub A9

13. The biomaterial as claimed in claim 11 or claim 12, characterized in that said tissue filling material is selected from the group consisting of collagen, gelatin, biological

Sub A1 adhesive, polymers of polylactic or polyglycolic acids and copolymers of polyethylene glycol and polylactide-co-glycolide.

Sub A10 14. The biomaterial as claimed in claim 11 or claim 12, characterized in that said tissue filling material is an osteoconductive material selected from the group consisting of coral, hydroxyapatite, a mixture of collagen and hydroxyapatite, tricalcic calcium phosphate, calcium sulfate and calcium carbonate.

Sub P11 15. A process for preparing the solid biomaterial as claimed in any one of claims 1 to 11 and 13, characterized in that it comprises the following steps:

crosslinking of at least one dextran derivative of general formula $DMC_aB_bSu_cS_d$ as defined in claim 1 or claim 2,

adsorption, in the insolubilized dextran derivative obtained above, of at least one growth factor as defined in any one of claims 1 to 4,

production of a solid biomaterial according to any one of claims 1 to 8 in the form of a hydrogel,

optionally, the freeze-drying of said hydrogel in order to obtain said biomaterial in the form of a powder.

Sub A12 16. The process as claimed in claim 15, characterized in that said crosslinking of at least one dextran derivative of general formula $DMC_aB_bSu_cS_d$ is carried out with the aid of a crosslinking agent as defined in claim 6 or claim 7.

Sub A13 17. The process as claimed in claim 15 or claim 16, characterized in that the crosslinking of at least one dextran derivative of general formula $DMC_aB_bSu_cS_d$ is carried out in the presence of a tissue filling material.

Sub A14 18. The process as claimed in claim 17, characterized in that said tissue filling material is as defined in claim 13 or claim 14.

Sub A15

19. A process for preparing the biomaterial as claimed in claim 12, characterized in that it comprises the following steps:

bringing the dextran derivative into contact with particles of an inorganic or polymeric insoluble support, as defined in claim 12, so as to obtain a composite,

insolubilization of the composite obtained above, in the presence of a crosslinking agent,

adsorption, in the insolubilized composite obtained above, of at least one growth factor as defined in claims 1 to 4.

Sub P10

20. The use of the solid biomaterial as claimed in any one of claims 1 to 14 for the preparation of a repair or filling material for osteoarticular, dental or maxillofacial applications.

Sub S17

21. The use as claimed in claim 20 for the preparation of osteoarticular, dental or maxillofacial implants.

Sub H12

22. The use of a solid biomaterial as claimed in any one of claims 1 to 14 for the preparation of a coating for orthopedic, dental or maxillofacial prostheses.

Sub A15

23. A functionalized prosthesis, characterized in that at least part of its surface is coated with a solid biomaterial as claimed in any one of claims 1 to 14.

Add b7